Genedata Biologics for Biopharma R&D at Ninth Annual PEGS

Latest advances in workflow system for biotherapeutics discovery will be showcased at leading protein engineering conference.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Genedata Biologics

Integrated tools for biologics R&D operations

Genedata has been able to solve major data integration and analysis problems in biotherapeutics R&D

Boston, MA (PRWEB) April 29, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the latest Genedata software solutions will be featured at the Ninth Annual PEGS. Genedata Biologics™, an end-to-end solution for biologics R&D, will be showcased in the PEGS Phage and Yeast Display of Antibodies and Recombinant Proteins Session. The presentation will detail screening automation use cases from phage, yeast, and mRNA displays, as well as hybridomas and B-cells. Advanced workflow support for affinity maturation, the design and evaluation of engineered molecules, and subsequent automated expression, purification, and characterization of novel biologics candidates using Genedata Biologics will be presented. Genedata Biologics and Genedata Expressionist® for Mass Spectrometry will also be featured in poster sessions at PEGS, the foremost protein engineering summit (Seaport World Trade Center; April 29 – May 3).

Genedata Biologics and Genedata Expressionist for Biologics R&D
Genedata provides dedicated data management solutions tailored to address specific requirements in biologics R&D. Simplifying and streamlining laborious and manual lab processes such as cloning, the Genedata Biologics platform increases efficiency and throughput while reducing data handling errors to improve results quality. Automating and standardizing protein characterization processes, Genedata Expressionist for Mass Spectrometry , for example, identifies and quantifies post-translational modifications (PTMs) of biotherapeutics to assess developability.

PEGS presentation and poster sessions will examine how Genedata enables more flexible and ultra high-throughput workflows, and how classic process bottlenecks can be removed. Concrete use cases will include:

  • High-throughput engineering, cloning and expression of multi-specific next-generation antibodies
  • Expression system optimization and bioprocess development
  • Automation of mass spectrometry data analysis for biotherapeutics

“Through our close collaboration over the last five years with industry leaders combined with significant investments in resources, Genedata has been able to solve major data integration and analysis problems in biotherapeutics R&D,” noted Dr. Othmar Pfannes, CEO of Genedata. “Our investments have created a unique software solution for R&D organizations in need of scientific data integration and analysis. And, we are fully committed to continuing these investments and expanding the solution so that it becomes the platform of choice for biopharmaceutical R&D as well as biotherapeutics and biosimilars manufacturing.”

Editorial Note: On April 29 at 12:10pm EST, Genedata Biologics will be featured in the PEGS Phage and Yeast Display of Antibodies and Recombinant Proteins Session -- “Automated High-throughput Antibody Discovery and Optimization” -- by Dr. Christopher Smith. To schedule a briefing contact, jackie.thrasivoulos genedata.com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Contact